postoperative cognitive function and sleep
Conditions
Interventions
Esketamine group: the analgesic pump adopts sufentanil 5µg/kg + esketamine 50mg + tosansetron 30mg + 0.9% sodium chloride solution with a capacity of 120ml.
Control group:The analgesic pump used sufentanil 5µg/kg + toxierise 30mg + 0.9% sodium chloride solution with a capacity of 120ml.
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria (1) Age= 45 years old (2) Undergo elective/limited gastrointestinal tumor surgery under general anesthesia, and the estimated operation time is = 2h (3) The operation can be completed before 20:00 , and the SICU will be admitted after the operation (4) The expected postoperative hospital stay= 3 days (5) Agree to use PCIA after surgery (6) Be able to understand the content of the assessment scale, and voluntarily sign the informed consent form by the patient himself or his family
Exclusion criteria
Exclusion criteria: Exclusion criteria Those who have one of the following conditions are not considered selected cases: (1) Severe central nervous system diseases (stroke, epilepsy, intracranial tumors, Parkinson's, craniocerebral trauma) (2) History of schizophrenia or a history of mental illness within 3 months or current use of antipsychotic drugs (including antidepressants and anxiolytics) (3) Inability to complete preoperative evaluation due to severe cognitive impairment (e.g., dementia, Alzheimer's) or hearing impairment (4) Have a history of drug or alcohol dependence or have taken sedative/hypnotic drugs within 1 month (5) Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic/diastolic blood pressure exceeding 180/100mmHg) (6) Patients at serious risk of increased intracranial pressure (7) Patients with untreated or undertreated hyperthyroidism (8) Extremely critical condition, (NYHA cardiac function grade III or LVEF <30%, liver function Child-Pugh grade C, preoperative dialysis treatment, ASA grade = IV, or expected survival =24 hours) (9) Patients who are allergic to esketamine (10) Refusal to participate in this study (11) Other researchers who believe that it is not suitable to participate in this study (specific reasons need to be specified)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of the N2 phase of the postoperative sleep cycle ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Various sleep parameters of polysomnography, including total sleep time, sleep efficiency, sleep fragmentation index, sleep time in each period (N1, N2, N3, REM sleep) and the percentage of N1, N3, REM sleep.;Analysis results of objective sleep indicators obtained by body motion recorder;RCQS sleep score;Athens insomnia score; | — |
Countries
China
Contacts
Public ContactHongyu Tan
Beijing Cancer Hospital
Outcome results
None listed